This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mujgan Sonmez, F. Articles by Topbas, M. Search for Related Content PubMed PubMed Citation Articles by Mujgan Sonmez, F. Articles by Topbas, M. Social Bookmarking                   What's this?

Effect of Antiepileptic Drugs on Plasma Lipids, Lipoprotein (a), and Liver Enzymes

Departments of Pediatrics,Child Neurology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey, fmsonmez{at}yahoo.com

Ercan Demir, MD

Departments of Pediatrics, Child Neurology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Asim Orem, MD

Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Sermet Yildirmis, PhD

Department of Biochemistry, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Fazil Orhan, MD

Departments of Pediatrics, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Adnan Aslan, MD

Department of Pediatrics, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

Murat Topbas, MD

Department of Public Health, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey

We conducted a study to assess the effect of phenobarbital, carbamazepine, and valproate on serum lipid profiles and lipoprotein (a) in 64 children with epilepsy (aged between 1 and 15 years) admitted to the child neurology outpatient clinic between July 2000 and July 2002. The children were separated as group 1 (18 children), treated with phenobarbital, 5 mg/kg/day; group 2 (22 children), treated with carbamazepine, 10 to 15 mg/kg/day; and group 3 (24 children), treated with sodium valproate, 20 mg/kg/day. Plasma lipoprotein (a), total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein A and apolipoprotein B levels, and liver enzymes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and -glutamyltransferase were determined before the initiation of the treatment and at 3, 6, and 12 months of the treatment period. The mean age of children in group 1 was significantly low compared with those in groups 2 and 3 (P < .05). The mean pretreatment lipid levels among the groups were not significantly increased. The mean lipoprotein (a) levels were significantly increased in all groups at 3, 6, and 12 months of the treatment period (P < .05). The increase in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol at 3, 6, and 12 months was statistically significant in group 1 (P < .05). The higher levels in lipoprotein (a) (mean > 30 mg/dL) were observed only in carbamazepine-treated patients at 6 and 12 months. The percentage of children with lipoprotein (a) levels over 30 mg/dL was 44%, 63%, and 33% in the phenobarbital-, carbamazepine-, and valproate-treated children, respectively. Antiepileptic drugs significantly increase the level of lipoprotein (a), which is a major risk factor for atherosclerosis, and also have variable effects on other lipid parameters. Lipoprotein (a) levels should be closely followed in patients receiving antiepileptic drugs. (J Child Neurol 2006;21:70—74).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?